BioSpace News Archive

Actify, a leader in innovative mental health treatment, is proud to support veteran care with the launch of Transcranial Magnetic Stimulation (TMS) in the State of Maryland.

Combining the best in imaging and pathology—Europe’s fastest-growing life science company, Perspectum, joins forces with a premier provider of pathology services, ProPath.

The trusted network of physical therapy franchises earns a coveted spot for a third time at #1263

August 20th, 2019, Novalis LifeSciences, an investment and advisory firm for the Life Science industry, announced today that it has raised $85M in capital for its first fund - Novalis LifeSciences Investments I, L.P.

In 2018, Minnesota apple lovers fell in love with First Kiss®, the newest apple variety from the University of Minnesota’s (UMN) apple breeding program.

ROMEG Therapeutics, an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the United States Patent and Trademark Office has issued two additional U.S. patents that are directed to the formulation, methods of use and administration of ROMEG’s proprietary colchicine oral solution, which will be marketed as GLOPERBA® and is currently indicated for prophylaxis of gout flares in adults.

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the pricing of an underwritten public offering of 6,871,727 shares of its common stock at a price to the public of $15.28 per share.

Medicinal Genomics Corp. (MGC), a pioneer in genomics and blockchain technology to improve the yield, safety and transparency of cannabis, today announced that Raphael Mechoulam will headline the list of more than 50 speakers and presenters at CannMed 2019, to be held September 23-24 at the Pasadena Convention Center, Pasadena CA.

InMode Ltd. (Nasdaq: INMD) (“InMode”) announced today the issuance and sale of an additional 500,000 ordinary shares pursuant to the partial exercise of the underwriters’ over-allotment option in connection with InMode’s initial public offering.

Kala Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.